Dr. Ai on Single-Agent and Combination Therapy in Patients With MDS

Jing Ai, MD
Published: Thursday, Apr 26, 2018



Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Ai says that choosing between single agent and combination therapy usually depends on the experience of the treating physician. Single agents are often used in the relapsed/refractory setting, as these patients have already failed 2 or 3 lines of therapy. Physicians turn to whatever has the best biological reason for use, Ai says.

From a clinical trial standpoint, MDS as compared with acute myeloid leukemia (AML) does not receive as much attention, even though the 2 diseases are biologically similar, Ai says. Her hope is that clinical trials for AML extend to patients with MDS to improve upon available treatment.
 


Jing Ai, MD, physician, Levine Cancer Institute, discusses the rationale behind single-agent therapy and the development of combination therapy in patients with myelodysplastic syndrome (MDS).

Ai says that choosing between single agent and combination therapy usually depends on the experience of the treating physician. Single agents are often used in the relapsed/refractory setting, as these patients have already failed 2 or 3 lines of therapy. Physicians turn to whatever has the best biological reason for use, Ai says.

From a clinical trial standpoint, MDS as compared with acute myeloid leukemia (AML) does not receive as much attention, even though the 2 diseases are biologically similar, Ai says. Her hope is that clinical trials for AML extend to patients with MDS to improve upon available treatment.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Expert Insights on the Management of Myeloproliferative Neoplasms: Evidence-based Approaches and Emerging Strategies to Address Challenges in CareSep 29, 20181.5
1st Annual LIVE Medical Crossfire®: Expert Exchanges in Hematologic Malignancies OnlineSep 30, 20188.0
Publication Bottom Border
Border Publication
x